Jan Astermark

131 – 140 of 191

show: 10
|
sort: year (new to old)

News feed Embed this list Save this search Mark all Export

Cancel

Embed this list

copy and paste the html snippet below into your own page:

<iframe src="https://lup.lub.lu.se/search/person/af7e247a-381e-4a1c-a1d8-7625b1488a9e?embed=1&amp;hide_pagination=1&amp;hide_info=1&amp;hide_options=1"
  width="100%"
  height="400"
  allowtransparency="true"
  frameborder="0">
</iframe>

« previous
1
…
13
14
15
16
…
20
next »

2008
Mark European principles of haemophilia care
Colvin, B. T. ; Astermark, Jan ^LU ; Fischer, K. ; Gringeri, A. ; Lassila, R. ; Schramm, W. ; Thomas, A. and Ingerslev, J. (2008) In Haemophilia 14(2). p.361-374
- Contribution to journal › Article
Mark Thrombin generation assay: a useful tool in the management of haemophilia A patients?
Salvagno, G ; Astermark, Jan ^LU ; Lippi, G ; Franchini, M ; Guidi, G and Berntorp, Erik ^LU (2008) XXVIIIth International Congress of the World Federation of Hemophilia, 2008 In Haemophilia 14(s2). p.26-26
- Contribution to journal › Published meeting abstract
Mark Value added: increasing the power to assess treatment outcome in joint haemorrhages
Donfield, S. M. ; Astermark, Jan ^LU ; Lail, A. E. ; Gilbert, S. A. and Berntorp, Erik ^LU (2008) In Haemophilia 14(2). p.276-280
- Contribution to journal › Article
Mark Variability of clinical manifestations of factor VII-deficiency in subjects homozygous or heterozygous for the F7 gene mutation A294V
Herrmann, Falko H. ; Wulff, Karin ; Strey, Rudiger ; Siegemund, Annelie ; Astermark, Jan ^LU and Schulman, Sam (2008) In Haematologica 93(8). p.1273-1275
- Contribution to journal › Letter
Mark Cost and outcome: comparisons of two alternative bypassing agents for persons with haemophilia A complicated by an inhibitor.
Steen Carlsson, Katarina ^LU ; Astermark, Jan ^LU ; Donfield, Sharyne and Berntorp, Erik ^LU (2008) In Thrombosis and Haemostasis 99(6). p.1060-1067
- Contribution to journal › Article
Mark Inhibitor development.
Astermark, Jan ^LU ; Lacroix-Desmazes, S and Reding, M T (2008) In Haemophilia 14 Suppl 3. p.36-42
- Contribution to journal › Article
Mark New risk factors for inhibitor development
Astermark, Jan ^LU (2008) XXVIIIth International Congress of the World Federation of Hemophilia, 2008 In Haemophilia 14(s2). p.43-43
- Contribution to journal › Published meeting abstract
Mark The importance of maintaining FVIII through levels above 1% during prophylactic treatment of hemophilia A: using license study databases to answer key medical questions
Collins, P ; Astermark, Jan ^LU ; Blanchette, V ; Bjorkman, S ; Fischer, K ; Casey, K ; Schroth, P ; Fritsch, S ; Oh, M and Spotts, G , et al. (2008) XXVIIIth International Congress of the World Federation of Hemophilia, 2008 In Haemophilia 14(s2). p.58-58
- Contribution to journal › Published meeting abstract
2007
Mark Impact of different inhibitor reactivities with commercial factor VIII concentrates on thrombin generation
Salvagno, G. L. ; Astermark, Jan ^LU ; Ekman, Maj ^LU ; Franchini, M. ; Midi, G. C. ; Lippi, G. ; Poli, G. and Berntorp, Erik ^LU (2007) In Haemophilia 13(1). p.51-56
- Contribution to journal › Article
Mark Negative effect of DNA hypermethylation on the outcome of intensive chemotherapy in older patients with high-risk myelodysplastic syndromes and acute myeloid leukemia following Myelodysplastic syndrome
Grovdal, Michael ; Khan, Rasheed ; Aggerholm, Anni ; Antunovic, Petar ; Astermark, Jan ^LU ; Bernell, Per ; Engstroem, Lena-Varia ; Kjeldsen, Lars ; Linder, Olle and Nilsson, Lars ^LU , et al. (2007) In Clinical Cancer Research 13(23). p.7107-7112
- Contribution to journal › Article

« previous
1
…
13
14
15
16
…
20
next »